Botox Injections in the Upper Face May Improve Mood and Self-Image Post-COVID
A Phase 1 trial examines whether Botulinum toxin in the glabella and forehead lifts mood and self-appearance satisfaction in returning Botox patients.
Summary
This completed Phase 1 clinical trial investigated whether Botox injections into the upper third of the face — targeting the glabella, forehead lines, and lateral canthal lines — could improve mood and self-appearance satisfaction in patients returning to treatment after the COVID-19 period. The study enrolled non-naïve Botox patients, meaning participants already had prior experience with the treatment, and used a placebo-controlled design. The research builds on earlier findings suggesting that paralyzing frown muscles may disrupt facial feedback loops that reinforce negative emotions. Conducted by DeNova Research, the trial explores a compelling intersection of cosmetic dermatology and mental wellness, asking whether reducing the physical expression of negative emotions might actually dampen the emotions themselves. Full results are not publicly available from the abstract alone.
Detailed Summary
The relationship between facial expression and emotional experience has long fascinated psychologists, and this clinical trial brings that question into the cosmetic dermatology setting. The so-called facial feedback hypothesis proposes that muscle movements involved in expressing emotions can amplify or even generate those feelings. If you can't frown deeply, the theory goes, you may feel less negative emotion. This trial tests that idea in a real-world clinical context.
Researchers at DeNova Research enrolled non-naïve Botox patients — individuals already familiar with the treatment — and assessed the impact of injecting Botulinum Neurotoxin into the upper third of the face: specifically the glabella (between the brows), forehead lines, and lateral canthal lines (crow's feet area). A placebo arm was included for comparison. The study was conducted in a post-COVID context, a period marked by elevated rates of anxiety, depression, and body image concerns, making mood outcomes particularly clinically relevant.
The trial was designed to measure two primary outcomes: changes in mood and self-appearance satisfaction following treatment. While specific numerical results are not available from the abstract, the completed status of the trial suggests data have been collected and likely analyzed.
The implications of this work extend beyond vanity. If Botox reliably improves mood — even modestly — it raises questions about whether cosmetic procedures might serve as adjunctive tools in managing mild mood disturbances. Conversely, it could reframe how clinicians discuss the psychological benefits of aesthetic medicine with patients.
Important caveats apply. The sample consisted of non-naïve patients, limiting generalizability to first-time users. The Phase 1 designation suggests the primary focus was safety and feasibility rather than efficacy. Additionally, this summary is based solely on the trial abstract, and full methodology and results are not yet publicly accessible.
Key Findings
- Trial tested whether Botox in the glabella and forehead improves mood via facial feedback mechanisms.
- Study enrolled non-naïve Botox patients during the post-COVID period, a time of heightened mood disruption.
- Placebo-controlled Phase 1 design suggests primary focus on safety and feasibility alongside mood outcomes.
- Self-appearance satisfaction was measured alongside mood, linking cosmetic outcomes to psychological wellbeing.
- Completed status indicates data collection is finished, though full results are not yet publicly available.
Methodology
Phase 1 placebo-controlled trial enrolling non-naïve Botox patients receiving injections to the glabella, forehead, and lateral canthal lines. Outcome measures included mood assessment and self-appearance satisfaction, evaluated in a post-COVID timeframe. Sponsored by DeNova Research; full methodology and sample size are not available from the abstract alone.
Study Limitations
This summary is based on the abstract only, as the full trial results and methodology are not publicly available. The use of non-naïve patients limits generalizability to first-time Botox users. Phase 1 designation means the trial was primarily designed for safety assessment rather than definitive efficacy conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.